Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France
Gabriel Tremblay, Clemence Cariou, Christian Recher, Mike Dolph, Patricia Brandt, Anne-Sandrine Blanc, Anna Forsythe
| Year of publication: |
2020
|
|---|---|
| Authors: | Tremblay, Gabriel ; Cariou, Clemence ; Recher, Christian ; Dolph, Mike ; Brandt, Patricia ; Blanc, Anne-Sandrine ; Forsythe, Anna |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 21.2020, 4, p. 543-555
|
| Subject: | Acute myeloid leukemia | FMS-like tyrosine kinase 3 | Cost-effectiveness analysis | Life years | Quality-adjusted life years | Incremental cost-effectiveness ratio | Kosten-Wirksamkeits-Analyse | Frankreich | France | Gesundheitskosten | Health care costs | Lebensqualität | Quality of life | Kosten-Nutzen-Analyse | Cost-benefit analysis |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-019-01149-9 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012421463